News Banner

MaxQ News

Posts about Partners news:

Fujifilm AI Platform in Clinical Use for ICH Detection and Diagnosis

Lexington, Mass., November 23, 2021 - FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced two of its customers are using the company’s REiLI Artificial Intelligence (AI) platform in clinical practice. Capital Health of Pennington, NJ is using this platform for a solution that automatically and rapidly identifies and prioritizes suspected Intracranial Hemorrhage (ICH) for potential stroke patients, and the University Radiology Group (URG) located throughout New Jersey is using the platform to support their accelerated detection and diagnosis of breast cancer.

“Fujifilm strategically developed REiLI as an open, vendor-neutral platform that manages workflow and delivers AI results through our Synapse 7x diagnostic applications,” said Bill Lacy, senior vice president, medical informatics, FUJIFILM Healthcare Americas Corporation. “This is the answer for Synapse customers as to how they can connect Fujifilm-developed, or in the case of Capital Health and URG, third-party algorithm results directly into their Synapse PACS diagnostic workflow in the most impactful ways to accelerate clinical decisions.”

The ACCIPIO® Suite of Clinical Artificial Intelligence Applications

MaxQ Dec 4, 2020 2:38:00 PM

MaxQ AI Partners with Fujifilm to Commercialize the ACCIPIO® Suite

Fujifilm enters multi-year global distribution agreement to deliver MaxQ’s ACCIPIO suite of clinical artificial intelligence applications through the FujiFilm Synapse PACS platform.

Tel Aviv, Israel – December 4th, 2020 – MaxQ AI, the industry-leading healthcare technology company that delivers comprehensive clinical workflow solutions assisting with improved patient triage and diagnosis, announced today –the multi-year partnership with FUJIFILM Medical Systems U.S.A., Inc., a leading provider of enterprise imaging solutions, to commercialize the Accipio Clinical Platform.

MaxQ AI to offer intracranial hemorrhage (ICH)

MaxQ Dec 4, 2019 6:03:00 PM

AI Software Applications on Blackford Platform

ACCIPIO® AI-powered tools assess non-contrast head CT images for intracranial hemorrhage prioritization and provide slice-level annotation

Edinburgh, UK & Tel Aviv, Israel – December 4, 2019 – Blackford, the centralized medical imaging platform, today announced that MaxQ AI’s CE Marked, TGA Approved Accipio Ix™ ICH solution for stroke and head trauma is now available on the Blackford Platform.

Developed by MaxQ AI, the ACCIPIO ICH and Stroke Platform with INSIGHT™ uses artificial intelligence in the assessment of non-contrast head CT images for suspected intracranial hemorrhage (ICH). Accipio Ix is intended for identification and prioritization, while Accipio Ax™ also includes slice-level annotation.

(ICH) Software to be Integrated on Philips’ Computed Tomography Systems

MaxQ Oct 15, 2019 10:41:00 AM

MaxQ AI Intracranial Hemorrhage (ICH)

MaxQ AI’s ACCIPIO® ICH and stroke software will be integrated on Philips Computed Tomography Systems.

Tel Aviv, Israel – October 15, 2019 MaxQ AI, the industry-leading medical diagnostic AI company, today announced that the company’s ACCIPIO® intracranial hemorrhage (ICH) and stroke software will be integrated on Philips’ computed tomography (CT) systems. The integration of ACCIPIO’s AI-powered solutions into Philips CT systems will support the detection of ICH to augment caregivers in identifying and prioritizing patients suffering from stroke, traumatic brain injury, head trauma, and other life-threatening conditions.

MaxQ AI Accelerates Artificial Intelligence Performance with Intel

MaxQ Feb 13, 2019 11:20:00 AM


Successful collaboration has accelerated the computational flow of MaxQ AI’s ACCIPIO® Medical Diagnostics Platform

Tel Aviv, Israel – February 13, 2019 – MaxQ AI, a medical diagnostic AI company, today announced that through its collaboration with Intel, it was able to triple the computational performance of its ACCIPIO intracranial hemorrhage (ICH) and stroke detection platform, enabling clinicians to prioritize critical patients and provide faster, near real-time ICH diagnosis. MaxQ AI’s ACCIPIO platform uses vision algorithms comprised of machine learning neural networks capable of reading all major CT OEMs’ non-contrast CT with a goal of providing speed and confidence in diagnosing suspected ICH. Accipio Ix™ has received both FDA clearance and CE Mark certification and is being deployed through major OEM CT and PACS partners to the global acute healthcare space.

MaxQ AI ACCIPIO Software Integrated as Part of GE Healthcare Platform

MaxQ Nov 27, 2018 3:59:00 PM

MaxQ AI ACCIPIO Software Integrated as Part of GE Healthcare’s Smart Subscription Platform Offering in the U.S. and E.U. Acute Care Markets

Select customers with GE CT scanners can now access and seamlessly integrate MaxQ AI’s revolutionary brain bleed detection software into their workflow via Smart Subscription

Tel Aviv, Israel and Andover, MA – November 27, 2018 – MaxQ AI, a clinical diagnostics intelligence platform company, and GE Healthcare, today announced that MaxQ AI’s ACCIPIO artificial intelligence (AI) platform will now be a part of GE Healthcare’s Computed Tomography (CT) Smart Subscription offering. GE Healthcare’s Smart Subscription provides customers with continuous access to the latest imaging software updates, through an available automatic download to their CT scanners from the cloud. As a Smart Subscription offering, hospitals with GE Healthcare CTs can easily and seamlessly integrate MaxQ AI’s ACCIPIO platform, of which Accipio Ix intracranial hemorrhage (ICH) detection software is now available, to support an acute care physician’s ability to identify and prioritize brain bleed stroke or head trauma.

Samsung NeuroLogica and MaxQ AI®

MaxQ Nov 20, 2018 4:08:00 PM

Announce Distribution Agreement

Agreement will pave the way for integration of MaxQ AI’s artificial intelligence Accipio Ix™ intracranial hemorrhage software into NeuroLogica’s medical imaging platforms in the U.S. and E.U. acute care market

Tel Aviv, Israel and Danvers, MA – November 20, 2018 – MaxQ AI , a clinical diagnostics intelligence platform company, and NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd., a leader in medical imaging technology, today announced a distribution agreement to integrate MaxQ AI’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ AI’s Accipio Ix, part of MaxQ AI’s unique ACCIPIO INSIGHT™ intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients, using adult non-contrast head computed tomography (CT) imaging.

Samsung NeuroLogica and MedyMatch Alliance to Bring “A.I. to the Curbside”

MaxQ Mar 29, 2017 5:43:00 PM

Samsung NeuroLogica and MedyMatch Technology Announce Strategic Alliance to Bring “A.I. to the Curbside”

March 29, 2017 – Tel Aviv, Israel, and Danvers, MA – MedyMatch Technology, Ltd. and Samsung NeuroLogica Corporation, the healthcare subsidiary of Samsung Electronics Co., Ltd., today announced a collaboration to integrate artificial intelligence (A.I.) clinical decision support applications with Samsung NeuroLogica’s medical imaging hardware in the acute care marketplace. This collaboration will create support tools that provide a second read capability to help caregivers quickly and accurately assess patients in prehospital environments.

Approach for Cognitive Healthcare Decision Support

MaxQ Jan 24, 2017 6:00:00 PM


  • IBM Watson Health Imaging signs multiyear OEM agreement to license MaxQ AI’s patient specific - point of care – cognitive decision support algorithms.
  • The first application to be made available is MaxQ AI’s A.I. based intracranial hemorrhage detection.
  • Go-To-Market will focus on the delivery of cognitive based clinical decision support tools to service the acute care marketplace through IBM Watson Health Imaging.

Tel Aviv, Israel – January 24, 2017 – IBM (NYSE: IBM) and MaxQ AI announced today a multi-year, go to market relationship to deliver MaxQ AI’s cognitive-based clinical decision support algorithms to the acute care marketplace. The initial application, to be distributed through IBM Watson Health Imaging’s platform is MaxQ AI’s intracranial hemorrhage detection algorithm.